Abstract. Multiple sclerosis (MS) is recognized to involve demyelination and axonal atrophy but accumulating evidence suggests that dysregulated sodium channel expression may also contribute to its pathophysiology. Recent studies have demonstrated that the expression of Na v 1.8 voltage-gated sodium channels, which are normally undetectable within the CNS, is upregulated in cerebellar Purkinje cells in experimental allergic encephalomyelitis (EAE) and MS, and suggest that the aberrant expression of these channels contributes to clinical dysfunction by distorting the firing pattern of these neurons. In this study we examined the temporal pattern of upregulation for Na v 1.8 mRNA and protein in chronic relapsing EAE by in situ hybridization and immunocytochemistry, respectively. Our results demonstrate a positive correlation between disease duration and degree of upregulation of Na v 1.8 mRNA and protein in Purkinje neurons in chronic-relapsing EAE. The progressive deterioration in clinical baseline scores (i.e. in clinical scores during remissions) is paralleled by a continued increase in Na v 1.8 mRNA and protein expression, but temporary worsening during relapses is not associated with transient changes in Na v 1.8 expression. These results provide evidence that the expression of sodium channel Na v 1.8 contributes to the development of clinical deficits in an in vivo model of neuroinflammatory disease.
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory CNS disorder in which loss of myelin (1) and axonal degeneration (2-4) produce clinical deficits. In addition, recent studies have implicated a third factor, dysregulated ion channel expression, in the pathophysiology of MS (5, review) .
Within the normal nervous system the sensory neuronspecific (SNS; Na v 1.8) sodium channel is expressed in a highly constrained manner within the somata and axons of small dorsal root (DRG) and trigeminal ganglia neurons, but is not detectable at significant levels within the CNS (6, 7) . However, expression of Na v 1.8 is upregulated within cerebellar Purkinje neurons in both genetic and autoimmune models of MS (8, 9) and in human MS (9) . Moreover, it has recently been demonstrated that annexin II/p11, a protein partner that binds to the N-terminus of Na v 1.8 and facilitates the insertion of functional channels into the neuronal membrane (10) , is also upregulated in Purkinje cells and colocalizes with Na v 1.8 within the cell somata and proximal dendritic tree in experimental allergic encephalomyelitis (EAE) and MS (11) .
Purkinje neurons are the only output neurons of the cerebellar cortex and the timing of action potentials and occurrence of bursting responses in these cells are critical in motor coordination and learning (12) (13) (14) . Unique electrophysiological characteristics, which include depolarized voltage-dependence (6, 7) , slow onset of inactivation (6, 7) , and rapid recovery from inactivation (15, 16) , endow Na v 1.8 channels with a wider dynamic range of activity than in most other sodium channels and indicate that abnormal expression of Na v 1.8 in Purkinje cells should have a significant impact on temporal firing properties. Consistent with this hypothesis, the functional expression of Na v 1.8 within Purkinje neurons in vitro results in markedly perturbed firing patterns, with increased action potential amplitude and duration, decreased frequency and complexity of complex bursts, and generation of sustained, pacemaker-like impulse trains that are not seen in the absence of Na v 1.8 (17) .
Cerebellar dysfunction in MS is closely correlated with disability (18) , exhibits increasing prevalence with length and severity of disease, and tends to be persistent (19) , but the basis for these phenomena is poorly understood. While growing evidence suggests that abnormal expression of Na v 1.8 may distort the pattern of Purkinje cell firing and thus contribute to cerebellar ataxia in MS and in models of MS such as EAE, to date there have been no studies on the temporal pattern of sodium channel Na v 1.8 upregulation, its relationship with persistent clinical deficit, or its relationship to clinical relapses. In this study we used immunocytochemistry and in situ hybridization cytochemistry to quantify the level of expression of sodium channel Na v 1.8 and examined its association with clinical course in a model of relapsing-remitting neuroinflammatory disease, chronic-relapsing EAE. Here we report that in chronic-relapsing EAE, the progressive deterioration in baseline clinical status is paralleled by a gradual, progressive increase in Na v 1.8 mRNA and protein within Purkinje cells, although relapses are not accompanied by transient increases in Na v 1.8 expression.
MATERIALS AND METHODS

Induction of EAE
Animal protocols followed guidelines established by the NIH and were approved by the Yale University Animal Care and Use Committee. Biozzi mice (Harlan, UK) aged 6 to 10 weeks were injected in the flank with 200 l emulsion composed of 1 mg spinal cord homogenate (SCH) or 300 g myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide (rat origin, synthesized by the W.M. Keck Biotechnology Resource Center, Yale University) in incomplete Freund's adjuvant (IFA; Sigma, St. Louis, MO) supplemented with 500 g of Mycobacterium (8:1 ratio of tuberculosis and butyricum; Difco, Detroit, MI). The SCH or MOG injection, with mycobacterium-supplemented IFA, was repeated in the alternate flank 1 week later. In addition, 500 ng pertussis toxin in 200 l PBS was administered i.p to each mouse coincident with the first SCH/MOG injection and repeated 48 hours later. There was no significant difference in the course of disease or in Na v 1.8 expression between MOG-(n ϭ 13) and SCH-induced (n ϭ 15) EAE mice (data not shown). This was not unexpected as the evolution and severity of disease were comparable between both groups (data not shown) and cerebellar lesions are well documented in both MOG- (20) and SCH-induced (21) EAE.
Clinical Assessment
Immunized mice were observed and scored on a 0 to 6 clinical scale with increasing clinical score reflecting clinical worsening as follows: 1-flaccid tail; 2-abnormal righting reflex and/or abnormal gait in the absence of weakness; 3-partial hindlimb paralysis; 4-complete hindlimb paralysis; 5-moribund; and 6-death. We applied the scale in 0.5 increments for scores Յ2, the range in which the scale includes cerebellar function. To determine the clinical course of EAE, defined relapses and remissions were identified by clinical scoring and applying the following algorithms: 1) relapses were identified by sustained (Ն4 days) increases in clinical score from baseline scores of at least 1.5 for the first relapse and 1.0 for subsequent relapses; 2) remissions were defined as improvement from the preceding relapse with a sustained (Ն4 days) decrease in clinical score of at least 1.0. Baseline clinical status, between each remission and the next relapse, was assessed using the same scale.
Tissue Collection
Mice (n ϭ 28) were killed at varying relapse-remission phases and lengths of disease (range 14-147 days) from date of induction of EAE, together with age-sex matched Biozzi mice controls (n ϭ 9). Mice were anesthetized with ketamine/xylazine (80/5 mg/kg, i.p.) and perfused through the heart with 4% paraformaldehyde in 0.14 M phosphate buffer. Cerebellar tissue was harvested and postfixed for 30 min in 4% paraformaldehyde in 0.14 M phosphate buffer (PBS), and cryoprotected overnight at 4ЊC in 30% sucrose in 0.14 M PBS
Immunocytochemistry
Sagittal cerebellar tissue sections incorporating the vermis/ intermediate regions from control (n ϭ 9) and EAE (n ϭ 28) were cut at 12 m onto slides desiccated overnight and processed for immunocytochemistry as previously described (8) . Briefly, sections were incubated in blocking solution (PBS containing 5% normal goat serum and 1% BSA) containing 0.1% Triton X-100 and 0.02% sodium azide at room temperature for 30 minutes, and then incubated with Na v 1.8 antibody (9) overnight at 4ЊC. Sections were then washed in PBS and incubated with goat anti-rabbit IgG-Cy3 secondary antibody (1:2,000; Amersham, Piscataway, NJ) in blocking solution for 3 hours, washed in PBS and mounted.
Control experiments, which included the omission of primary or secondary antibodies, showed no fluorescent signal (data not shown).
In Situ Hybridization
Sagittal cerebellar tissue sections incorporating the vermis/ intermediate region from control (n ϭ 5) and EAE (n ϭ 15) were cut at 12 m and were placed onto slides and desiccated overnight. Sections were processed for in situ hybridization cytochemistry as previously described using an isoform-specific riboprobe to Na v 1.8 (22) , except that incubation in 4% paraformaldehyde was increased to 12 min and permeabilization with proteinase K was reduced to 6 min. Sense riboprobes yielded no signals on in situ hybridization (data not shown).
Data Acquisition and Analysis
Images were captured within a linear range of optical intensity using a Nikon Eclipse E800 light microscope. Semiquantitative microdensitometry of in situ hybridization and immunofluorescent signals was performed using IPLab Scientific Image Processing software (Scanalytics Inc., Fairfax, VA). During analysis of the sections we observed an increased tendency for upregulation of Na v 1.8 mRNA and protein within the anterior vermis/intermediate zone (lobules II-V) (Fig. 1, inset A) compared to posterior vermis (Fig. 1, inset B) , although Na v 1.8 was upregulated in both regions. The anterior vermis/intermediate region is the predominant afferent target of mossy fibers input derived from the spinocerebellar tracts (23) (24) (25) and plays an important role in motor coordination of truncal and limb movements, and for this reason the anterior vermis/intermediate region was preferentially selected for analysis. Multiple images were taken from the anterior vermis/intermediate zone and a random sample was selected for analysis of 80 to 120 Purkinje neurons per animal. Signal intensities were obtained by manual outlining of Purkinje cells using the IPLab integrated densitometry function to calculate mean signal intensities for the outlined areas (22) . Background signal was subtracted from both 
RESULTS
Clinical Course of EAE
Mice induced with EAE demonstrated a chronic relapsing-remitting pattern of disease (Fig. 2) . Clinical status improved (clinical scores decreased) by approximately 2.0 during each remission, but did not return to control levels, and the baseline clinical status between relapses worsened after each successive relapse (Fig. 2) . The mean time to first, second, and third relapse was 27.8 Ϯ 3.9 days, 56.8 Ϯ 7.4 days, and 80.7 Ϯ 9.9 days, respectively.
Level of Expression of Na v 1.8 Rises with Duration of Disease and Accumulated Clinical Score
In cerebellums of mice with EAE we first observed a significant upregulation of Na v 1.8 protein (21.7 Ϯ 2.4, n ϭ 4) compared to control (11.4 Ϯ 1.4, n ϭ 9; p Ͻ 0.05) at 51 to 75 days, compared to 0 to 25 and 26 to 50 days from induction of EAE, with a progressive increase in Na v 1.8 protein levels thereafter. Upregulation of Na v 1.8 protein was paralleled by changes in Na v 1.8 mRNA.
There was a positive correlation between duration of disease and the level of expression of Na v 1.8 mRNA (r ϭ 0.72, p Ͻ 0.01) and protein (r ϭ 0.63, p Ͻ 0.005) (Figs. 3A, B, 4) . Although all mice displayed a relapsingremitting course of EAE, the time to onset of relapse or remission varied as noted above. We therefore also examined the expression of Na v 1.8 mRNA and protein as a function of total accumulated clinical score (cumulative sum of all daily scores for duration of disease, which provides a measure of disease load). As seen in Figures  3C, D and 4 , there was a positive correlation between accumulated clinical score and expression of Na v 1.8 mRNA (r ϭ 0.76, p Ͻ 0.005) and protein (r ϭ 0.62, p Ͻ 0.005). The upregulation of Na v 1.8 protein was manifested both by an increased frequency of Na v 1.8-immunopositive Purkinje neurons, which rose from 19.7% Ϯ 8.7% (n ϭ 3) at 0 to 25 days duration of disease to 88.4% Ϯ 2.2% (n ϭ 5, p Ͻ 0.05) at 125 to 150 days duration of disease (Fig. 5) , and by an increased intensity of immunofluorescence with duration of disease (Fig. 4b, d , f, h).
Upregulation of Na v 1.8 Protein Is Associated with Accrual of Baseline Clinical Deficit
Our results demonstrate that as the disease course progresses there is a significant accrual of baseline clinical deficit, manifested by a progressive failure of the clinical scores to return to the control level of 0 during remissions. This can be seen in Figure 6A , which compares the clinical score during the third remission (2.1 Ϯ 0.4, n ϭ 6) with the clinical score during the first remission (0.5 Ϯ 0.1, n ϭ 4; p Ͻ 0.05). The increase in baseline clinical deficit between the first and third remissions is associated with a significant increase in Na v 1.8 protein, which is present at a higher level during the third remission (30.7 Ϯ 4.8, n ϭ 6) compared to first remission (14.4 Ϯ 3.4, n ϭ 4; p Ͻ 0.05) (Fig. 6B) .
Na v 1.8 Expression Is Correlated with Deteriorating Baseline Status but not with Clinical Relapse
As seen in Figure 2 , the clinical course in this EAE model is characterized by relapses and remissions that are superimposed on a gradual but continuous deterioration of baseline status (i.e. clinical status between relapses). To determine whether the level of Na v 1.8 protein increased and then decreased during relapses and remissions, or rose in a more continuous manner throughout the course of the disease, we quantified the level of Na v 1.8 immunostaining during each relapse and the following remission. We did not observe a transient increase in Na v 1.8 during the first, second or third relapse. Figure  6C and D show the results for the third relapse and the subsequent remission. Although there is a significant difference in clinical score between the third relapse (3.8 Ϯ 0.3, n ϭ 4) and remission (2.1 Ϯ 0.4, n ϭ 6; p Ͻ 0.05) (Fig. 6C) , there is not a significant difference in the level of expression of Na v 1.8 protein at the third relapse (26.8 Ϯ 2.7, n ϭ 4) compared to third remission (30.7 Ϯ 4.8, n ϭ 6; p ϭ 0.4) (Fig. 6D) . Analyses of the first relapse/ remission and second relapse/remission yielded similar results (data not shown).
DISCUSSION
In this study we examined the time course of expression of sodium channel Na v 1.8 in a model of chronic relapsing EAE, and demonstrated a positive correlation between the level of Na v 1.8 expression (which includes increased Na v 1.8 mRNA, Na v 1. (Fig. 4) , there is an increased proportion of Purkinje neurons that are immunopositive for Na v 1.8 protein with increasing duration of disease.
in the number of Na v 1.8-immunopositive Purkinje neurons) and duration of disease and total accumulated clinical score. We observed a continuing deterioration of baseline clinical status (i.e. a progressive accrual of nonremitting clinical deficit, which increased to a level of 2.1 Ϯ 0.4 by the third remission). The deterioration in baseline clinical score occurred over a range that includes cerebellar dysfunction (a score of 2.0 corresponds to abnormal righting reflex and/or abnormal gait in the absence of hind limb paralysis). The continuing deterioration of baseline clinical status was paralleled by a progressive upregulation of Na v 1.8 protein. In contrast, clinical relapses were not associated with transient changes in Na v 1.8 sodium channel expression (Fig. 7) .
Neuronal electrogenesis in any given type of neuron, including the Purkinje cell, is dependent on the repertoire of sodium channels that are present (26) (27) (28) . Abnormal expression of sodium channels within mutant mice models has been shown to lead to perturbations of Purkinje cell firing that can produce ataxia (29, 30) . Within the normal nervous system, the expression of sodium channels within Purkinje neurons is confined to Na v 1.1, Na v 1.2, and Na v 1.6 (6, 31, 32), whereas Na v 1.8 sodium channels are selectively expressed within the DRG and trigeminal ganglia and are not normally detectable with Purkinje cells (6, 7) . However, there is aberrant expression of Na v 1.8 within Purkinje cells in both genetic and autoimmune models of MS (8, 9) and human MS (9) . The abnormal expression of Na v 1.8 in Purkinje cells in EAE and MS has been linked with an upregulation of annexin II/p11 (a protein partner of Na v 1.8 that facilitates the insertion of functional channels into the neuronal membrane [10] ), and it has been shown that annexin II/ p11 is colocalized with Na v 1.8 in EAE and MS (11) .
Although the neuronal expression of sodium channels demonstrates considerable dynamic plasticity, the molecular mechanisms that underlie the upregulation of Na v 1.8 in Purkinje neurons in EAE and MS are not yet understood. It is possible that inflammatory mediators play a role in the upregulation of Na v 1.8 in Purkinje cells in EAE and MS. Consistent with this hypothesis, Tanaka et al (33) reported the upregulation of Na v 1.8 gene transcription in DRG neurons following injection of carrageenan, which produces inflammatory pain within the peripheral projection fields of these cells. However, as inflammatory changes have not been observed in the taiep rat (34), a mutant model of CNS demyelination, the upregulation of Na v 1.8 mRNA and protein in taiep Purkinje cells (8) argues against an inflammatory driven process. Purkinje cell axon transection does not evoke an upregulation of Na v 1.8 mRNA or protein (35) . One attractive mechanism for the upregulation of Na v 1.8 in Purkinje cells of EAE and MS involves neurotrophic factors. Neurotrophins demonstrate differential sub-type specific modulatory effects on sodium channel expression, including the upregulation of Na v 1.8 gene transcription by nerve growth factor (NGF) and glial-derived neurotrophic factor (GDNF) (36, 37) . Elevated NGF levels have been demonstrated in both human (38) and animal (39, 40) A, B) . Histograms demonstrating a significant deterioration in clinical score when third remission is compared to first remission (A). This represents a nonremitting deficit that includes cerebellar dysfunction (impaired righting reflex and abnormal gait in the absence of weakness). Expression of Na v 1.8 protein is significantly increased during third, compared to first, remission (B). * ϭ p Ͻ 0.05. Na v 1.8 is not transiently upregulated during relapses (C, D). Histogram demonstrating a significant difference in clinical score when third remission and third relapse are compared (C); * ϭ p Ͻ 0.05. In contrast, there is not a significant difference in Na v 1.8 protein expression between the third remission and relapse (D).
in EAE (41) . Studies are currently ongoing to further elucidate the role of NGF in the upregulation of Na v 1.8 protein in Purkinje cells of EAE.
Electrophysiological studies indicate that abnormal expression of Na v 1.8 distorts the firing pattern of Purkinje cells. The electrophysiological properties of Na v 1.8, which include slow onset of inactivation (6, 7), depolarized voltage-dependence of inactivation (6, 7) , and rapid recovery from inactivation (15, 16) , result in Na v 1.8 channels being available over a wider range of dynamic activity than the sodium channel subtypes that are normally expressed within Purkinje cells. Computer modeling (42) and electrophysiological studies (43) in DRG neurons indicate that insertion of functional channels into the neuronal membrane alters not only action potential configuration but also action potential generation, leading to the prediction that abnormal expression of Na v 1.8 within Purkinje cells should have a large impact on their firing properties. This is supported by recent in vitro studies using biolistic gene expression techniques, which show that expression of Na v 1.8 within Purkinje neurons leads to markedly distorted firing patterns that include increased action potential amplitude and duration, decreased frequency and complexity of impulse bursts, and generation of sustained, pacemaker-like impulse trains that are not observed in the absence of Na v 1.8 (17) . Thus it is likely that aberrant Na v 1.8 expression perturbs both simple spike and complex spike electrogenesis in Purkinje cells, both of which have been proposed to play important roles in motor control and motor learning (12, 14) .
Our results, which show that there is a correlation between Na v 1.8 levels in Purkinje neurons and the degree of baseline clinical deterioration in EAE, add to the evidence indicating that the aberrant expression of Na v 1.8 channels within Purkinje cells can contribute to neurologic abnormalities. Lesions within the cerebellum have been associated with increased disability in MS (44, 45) and are known to be frequently persistent, without significant remission (19) . Our observations of a progressive change in Na v 1.8 sodium channel expression in Purkinje cells, which increases monotonically in parallel with a progressive deterioration of baseline clinical status, provide the first demonstration of an association between dysregulated sodium channel expression and clinical dysfunction in a model of neuroinflammatory disease. The present results suggest that molecular pathology, i.e. an acquired channelopathy, within Purkinje neurons can impair cerebellar function, thereby contributing to clinical symptomology in these disorders.
